30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Arcturus Therapeutics Holdings Inc (ARCT)

Track

The most recent insider trading activity occurred on October 15, 2024, with proposed and planned sales by Officer Pad Chivukula totaling approximately $249,120. Earlier transactions in June 2024 included significant proposed and actual sales by Director Andy Sassine and Officer Pad Chivukula. These transactions primarily represent sales by company insiders.
Stock chart
Ticker: ARCT Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Chivukula Pad
Chief Scientific Officer & COO
2 sales — total 498,242 USD
Planned sale 15 Oct 2024
Value US$961,039.75 | Price 431.18 | Shares 91,598
Proposed sale 15 Oct 2024
Value US$2,177,593.94 | Price 244.70 | Shares 73,928
Sale 12 Jun 2024
Value US$2,497,755.31 | Price 34.02 | Shares 92,478
Proposed sale 12 Jun 2024
Value US$4,130,824.30 | Price 470.75 | Shares 28,987
Proposed sale 10 Jun 2024
Value US$64,000.00 | Price 32.00 | Shares 2,000
Planned sale 5 Jun 2024
Value US$5,130.00 | Price 45.00 | Shares 114
Proposed sale 5 Jun 2024
Value US$1,665,000.00 | Price 45.00 | Shares 37,000
Planned sale 3 Jun 2024
Value US$1,040,234.00 | Price 40.01 | Shares 26,000
Proposed sale 3 Jun 2024
Value US$1,040,234.21 | Price 40.01 | Shares 26,000
Planned sale 25 Mar 2024
Value US$610,573.70 | Price 35.02 | Shares 17,435
Planned sale 19 Mar 2024
Value US$299,839.24 | Price 35.01 | Shares 8,565
Proposed sale 19 Mar 2024
Value US$910,000.00 | Price 35.00 | Shares 26,000
Planned sale 1 Nov 2023
Value US$93,601.50 | Price 18.72 | Shares 5,000
Planned sale 2 Oct 2023
Value US$128,061.50 | Price 25.61 | Shares 5,000
Proposed sale 2 Oct 2023
Value US$390,000.00 | Price 26.00 | Shares 15,000
Planned sale 1 Sep 2023
Value US$157,263.50 | Price 31.45 | Shares 5,000
Proposed sale 1 Sep 2023
Value US$155,000.00 | Price 31.00 | Shares 5,000
Planned sale 1 Aug 2023
Value US$174,550.00 | Price 34.91 | Shares 5,000
Proposed sale 1 Aug 2023
Value US$175,000.00 | Price 35.00 | Shares 5,000
Planned sale 14 Jul 2023
Value US$243,880.00 | Price 35.00 | Shares 6,968
Planned sale 14 Jul 2023
Value US$875,250.00 | Price 35.01 | Shares 25,000
Proposed sale 14 Jul 2023
Value US$875,336.50 | Price 35.01 | Shares 25,000
Proposed sale 14 Jul 2023
Value US$243,880.00 | Price 35.00 | Shares 6,968
Planned sale 3 Jul 2023
Value US$143,750.00 | Price 28.75 | Shares 5,000
Planned sale 1 Jun 2023
Value US$135,800.00 | Price 27.16 | Shares 5,000
Planned sale 11 May 2023
Value US$239,652.00 | Price 30.24 | Shares 7,925
Proposed sale 11 May 2023
Value US$239,681.74 | Price 30.24 | Shares 7,925
Planned sale 10 May 2023
Value US$512,250.00 | Price 30.00 | Shares 17,075
Proposed sale 10 May 2023
Value US$512,287.00 | Price 30.00 | Shares 17,075
Planned sale 1 May 2023
Value US$129,650.00 | Price 25.93 | Shares 5,000
Planned sale 18 Apr 2023
Value US$196,358.24 | Price 28.18 | Shares 6,968
Proposed sale 17 Apr 2023
Value US$196,342.91 | Price 28.18 | Shares 6,968
Planned sale 3 Apr 2023
Value US$126,900.00 | Price 25.38 | Shares 5,000
Planned sale 6 Mar 2023
Value US$80,350.00 | Price 16.07 | Shares 5,000
Buy 15 Dec 2022
Value US$39,996.00 | Price 18.00 | Shares 2,222
Buy 23 Nov 2022
Value US$82,550.00 | Price 16.51 | Shares 5,000
Planned sale 4 Jan 2022
Value US$324,000.00 | Price 40.00 | Shares 8,100
Planned sale 16 Dec 2021
Value US$145,327.63 | Price 40.00 | Shares 3,633
Planned sale 8 Dec 2021
Value US$254,680.00 | Price 40.00 | Shares 6,367
Planned sale 1 Nov 2021
Value US$444,100.00 | Price 44.41 | Shares 10,000
Planned sale 1 Oct 2021
Value US$443,600.00 | Price 44.36 | Shares 10,000
Planned sale 1 Apr 2021
Value US$429,500.00 | Price 42.95 | Shares 10,000
Planned sale 1 Mar 2021
Value US$542,300.00 | Price 54.23 | Shares 10,000
Planned sale 1 Feb 2021
Value US$753,100.00 | Price 75.31 | Shares 10,000
Planned sale 4 Jan 2021
Value US$464,000.00 | Price 46.40 | Shares 10,000
Sale 9 Dec 2020
Value US$33,975,042.65 | Price 94.97 | Shares 357,745
Sale 8 Dec 2020
Value US$46,675,592.70 | Price 105.54 | Shares 442,255
Planned sale 1 Dec 2020
Value US$961,900.00 | Price 96.19 | Shares 10,000
Planned sale 2 Nov 2020
Value US$552,800.00 | Price 55.28 | Shares 10,000
Planned sale 1 Oct 2020
Value US$428,300.00 | Price 42.83 | Shares 10,000
Planned sale 3 Sep 2020
Value US$451,600.00 | Price 45.16 | Shares 10,000
Buy 12 Jun 2020
Value US$14,998.50 | Price 33.33 | Shares 450
Buy 10 Jun 2020
Value US$31,690.00 | Price 31.69 | Shares 1,000
Buy 10 Jun 2020
Value US$148,700.00 | Price 29.74 | Shares 5,000
Buy 5 Dec 2019
Value US$54,964.77 | Price 9.73 | Shares 5,649
Buy 3 Dec 2019
Value US$100,000.00 | Price 10.00 | Shares 10,000
Buy 13 Sep 2019
Value US$24,334.00 | Price 10.58 | Shares 2,300
Buy 12 Sep 2019
Value US$5,346.70 | Price 10.69 | Shares 500
Buy 29 Aug 2019
Value US$56,100.00 | Price 11.22 | Shares 5,000
Buy 23 Aug 2019
Value US$109,000.00 | Price 10.90 | Shares 10,000
Buy 20 Aug 2019
Value US$48,087.20 | Price 10.85 | Shares 4,432
Buy 19 Aug 2019
Value US$51,584.62 | Price 11.02 | Shares 4,681
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2024-10-16 2024-10-15 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
91,598 +17.5%
431.18
US$961,040 		91,598 +17.5% 431.18 US$961,040
2024-10-15 2024-10-15 PrS Proposed sale
Chivukula Pad

Officer

Officer
73,928
244.70
US$2,177,594 		73,928 244.70 US$2,177,594
2024-06-14 2024-06-12 S Sale
3.0
SASSINE ANDY

Chief Financial Officer

Executive Director
92,478 -25.2%
34.02
US$2,497,755 		92,478 -25.2% 34.02 US$2,497,755
2024-06-12 2024-06-12 PrS Proposed sale
3.0
SASSINE ANDY

Director

Non-Executive Director
50,000
32.03
US$1,601,500 		50,000 32.03 US$1,601,500
2024-06-18 2024-06-10 PrS Proposed sale
3.6
Kummerfeld Keith C

Officer

Officer
2,000
32.00
US$64,000 		2,000 32.00 US$64,000
2024-06-07 2024-06-05 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
114 -0.0%
45.00
US$5,130 		114 -0.0% 45.00 US$5,130
2024-06-05 2024-06-05 PrS Proposed sale
Chivukula Pad

Officer

Officer
37,000
45.00
US$1,665,000 		37,000 45.00 US$1,665,000
2024-06-04 2024-06-03 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
26,000 -5.5%
40.01
US$1,040,234 		26,000 -5.5% 40.01 US$1,040,234
2024-06-03 2024-06-03 PrS Proposed sale
Chivukula Pad

Officer

Officer
26,000
40.01
US$1,040,234 		26,000 40.01 US$1,040,234
2024-03-27 2024-03-25 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
17,435 -3.6%
35.02
US$610,574 		17,435 -3.6% 35.02 US$610,574
2024-03-21 2024-03-19 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
8,565 -1.7%
35.01
US$299,839 		8,565 -1.7% 35.01 US$299,839
2024-03-19 2024-03-19 PrS Proposed sale
Chivukula Pad

Officer

Officer
26,000
35.00
US$910,000 		26,000 35.00 US$910,000
2023-11-03 2023-11-01 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
5,000 -1.0%
18.72
US$93,602 		5,000 -1.0% 18.72 US$93,602
2023-10-04 2023-10-02 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
5,000 -1.0%
25.61
US$128,062 		5,000 -1.0% 25.61 US$128,062
2023-10-02 2023-10-02 PrS Proposed sale
Chivukula Pad

Officer

Officer
15,000
26.00
US$390,000 		15,000 26.00 US$390,000
2023-09-05 2023-09-01 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
5,000 -1.0%
31.45
US$157,264 		5,000 -1.0% 31.45 US$157,264
2023-09-01 2023-09-01 PrS Proposed sale
Chivukula Pad

Officer

Officer
5,000
31.00
US$155,000 		5,000 31.00 US$155,000
2023-08-03 2023-08-01 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
5,000 -1.0%
34.91
US$174,550 		5,000 -1.0% 34.91 US$174,550
2023-08-01 2023-08-01 PrS Proposed sale
Chivukula Pad

Officer

Officer
5,000
35.00
US$175,000 		5,000 35.00 US$175,000
2023-07-18 2023-07-14 PlS Planned sale
3.6
Kummerfeld Keith C

See Remarks

Officer
6,968 -88.0%
35.00
US$243,880 		6,968 -88.0% 35.00 US$243,880
2023-07-18 2023-07-14 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
25,000 -4.6%
35.01
US$875,250 		25,000 -4.6% 35.01 US$875,250
2023-07-14 2023-07-14 PrS Proposed sale
Chivukula Pad

Officer

Officer
25,000
35.01
US$875,336 		25,000 35.01 US$875,336
2023-07-14 2023-07-14 PrS Proposed sale
3.6
KEITH C KUMMERFELD

Officer

Officer
6,968
35.00
US$243,880 		6,968 35.00 US$243,880
2023-07-07 2023-07-03 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
5,000 -0.9%
28.75
US$143,750 		5,000 -0.9% 28.75 US$143,750
2023-06-05 2023-06-01 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
5,000 -0.9%
27.16
US$135,800 		5,000 -0.9% 27.16 US$135,800
2023-05-12 2023-05-11 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
7,925 -1.4%
30.24
US$239,652 		7,925 -1.4% 30.24 US$239,652
2023-05-11 2023-05-11 PrS Proposed sale
Chivukula Pad

Officer

Officer
7,925
30.24
US$239,682 		7,925 30.24 US$239,682
2023-05-12 2023-05-10 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
17,075 -2.9%
30.00
US$512,250 		17,075 -2.9% 30.00 US$512,250
2023-05-10 2023-05-10 PrS Proposed sale
Chivukula Pad

Officer

Officer
17,075
30.00
US$512,287 		17,075 30.00 US$512,287
2023-05-03 2023-05-01 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
5,000 -0.9%
25.93
US$129,650 		5,000 -0.9% 25.93 US$129,650
2023-04-19 2023-04-18 PlS Planned sale
3.6
Kummerfeld Keith C

See Remarks

Officer
6,968 -88.0%
28.18
US$196,358 		6,968 -88.0% 28.18 US$196,358
2023-04-17 2023-04-17 PrS Proposed sale
3.6
KEITH C KUMMERFELD

Officer

Officer
6,968
28.18
US$196,343 		6,968 28.18 US$196,343
2023-04-05 2023-04-03 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
5,000 -0.8%
25.38
US$126,900 		5,000 -0.8% 25.38 US$126,900
2023-03-08 2023-03-06 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
5,000 -0.8%
16.07
US$80,350 		5,000 -0.8% 16.07 US$80,350
2022-12-19 2022-12-15 B Purchase
1.9
Marquet Magda
Non-Executive Director
2,222 +9.8%
18.00
US$39,996 		2,222 +9.8% 18.00 US$39,996
2022-11-28 2022-11-23 B Purchase
3.3
Payne Joseph E

President and CEO

Executive Director
5,000 +0.3%
16.51
US$82,550 		5,000 +0.3% 16.51 US$82,550
2022-01-06 2022-01-04 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
8,100 -1.3%
40.00
US$324,000 		8,100 -1.3% 40.00 US$324,000
2021-12-20 2021-12-16 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
3,633 -0.6%
40.00
US$145,328 		3,633 -0.6% 40.00 US$145,328
2021-12-10 2021-12-08 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
6,367 -1.0%
40.00
US$254,680 		6,367 -1.0% 40.00 US$254,680
2021-11-03 2021-11-01 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
10,000 -1.6%
44.41
US$444,100 		10,000 -1.6% 44.41 US$444,100
2021-10-04 2021-10-01 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
10,000 -1.6%
44.36
US$443,600 		10,000 -1.6% 44.36 US$443,600
2021-04-05 2021-04-01 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
10,000 -1.5%
42.95
US$429,500 		10,000 -1.5% 42.95 US$429,500
2021-03-03 2021-03-01 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
10,000 -1.5%
54.23
US$542,300 		10,000 -1.5% 54.23 US$542,300
2021-02-03 2021-02-01 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
10,000 -1.5%
75.31
US$753,100 		10,000 -1.5% 75.31 US$753,100
2021-01-05 2021-01-04 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
10,000 -1.4%
46.40
US$464,000 		10,000 -1.4% 46.40 US$464,000
2020-12-10 2020-12-09 S Sale
3.6
Ultragenyx Pharmaceutical Inc.
Non-Executive Director Large shareholder
357,745 -14.0%
94.97
US$33,975,043 		357,745 -14.0% 94.97 US$33,975,043
2020-12-10 2020-12-08 S Sale
3.6
Ultragenyx Pharmaceutical Inc.
Non-Executive Director Large shareholder
442,255 -14.7%
105.54
US$46,675,593 		442,255 -14.7% 105.54 US$46,675,593
2020-12-03 2020-12-01 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
10,000 -1.4%
96.19
US$961,900 		10,000 -1.4% 96.19 US$961,900
2020-11-03 2020-11-02 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
10,000 -1.4%
55.28
US$552,800 		10,000 -1.4% 55.28 US$552,800
2020-10-02 2020-10-01 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
10,000 -1.4%
42.83
US$428,300 		10,000 -1.4% 42.83 US$428,300
2020-09-04 2020-09-03 PlS Planned sale
Chivukula Pad

Chief Scientific Officer & COO

Officer
10,000 -1.4%
45.16
US$451,600 		10,000 -1.4% 45.16 US$451,600
2020-06-12 2020-06-12 B Purchase
3.6
Kummerfeld Keith C

See Remarks

Officer
450 +90.0%
33.33
US$14,998 		450 +90.0% 33.33 US$14,998
2020-06-10 2020-06-10 B Purchase
3.3
Payne Joseph E

President and CEO

Executive Director
1,000 +0.1%
31.69
US$31,690 		1,000 +0.1% 31.69 US$31,690
2020-06-10 2020-06-10 B Purchase
3.0
SASSINE ANDY

Chief Financial Officer

Executive Director
5,000 +1.9%
29.74
US$148,700 		5,000 +1.9% 29.74 US$148,700
2019-12-09 2019-12-05 B Purchase SASSINE ANDY

Chief Financial Officer

Executive Director
5,649 +2.2%
9.73
US$54,965 		5,649 +2.2% 9.73 US$54,965
2019-12-05 2019-12-03 B Purchase SASSINE ANDY

Chief Financial Officer

Executive Director
10,000 +4.0%
10.00
US$100,000 		10,000 +4.0% 10.00 US$100,000
2019-09-17 2019-09-13 B Purchase
1.9
Marquet Magda
2,300 +11.3%
10.58
US$24,334 		2,300 +11.3% 10.58 US$24,334
2019-09-12 2019-09-12 B Purchase
3.6
Kummerfeld Keith C

See Remarks
500 +inf%
10.69
US$5,347 		500 +inf% 10.69 US$5,347
2019-08-30 2019-08-29 B Purchase Payne Joseph E

President and CEO

Executive Director Large shareholder
5,000 +0.3%
11.22
US$56,100 		5,000 +0.3% 11.22 US$56,100
2019-08-26 2019-08-23 B Purchase SASSINE ANDY

Chief Financial Officer

Officer
10,000 +4.2%
10.90
US$109,000 		10,000 +4.2% 10.90 US$109,000
2019-08-21 2019-08-20 B Purchase FARRELL PETER C Non-Executive Director
4,432 +11.5%
10.85
US$48,087 		4,432 +11.5% 10.85 US$48,087
2019-08-21 2019-08-19 B Purchase FARRELL PETER C Non-Executive Director
4,681 +13.8%
11.02
US$51,585 		4,681 +13.8% 11.02 US$51,585
Explore more

More insider trading research around Arcturus Therapeutics Holdings Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America